Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.71 USD | -1.50% | +3.62% | +20.97% |
07/05 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
07/05 | Transcript : Halozyme Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.97% | 569.04Cr | |
+9.42% | 11TCr | |
+11.84% | 11TCr | |
-1.05% | 2.2TCr | |
-14.15% | 2.19TCr | |
-5.29% | 1.92TCr | |
-4.16% | 1.81TCr | |
-38.29% | 1.77TCr | |
+7.99% | 1.43TCr | |
+36.24% | 1.24TCr |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q1 EPS $0.79, vs. Street Est of $0.70